Medicines advertising5 min read

Medicines advertising in Belgium: what needs review before publication?

See what to send for pre-publication review in Belgium, with separate examples for public OTC and healthcare professional materials.

Hendrik StaelsIndustrial pharmacist, founder of MEDCOR
Reviewed by Hendrik

Published Also available inNederlandsFrançais

ShareLinkedInWhatsAppEmail

Before a medicine’s promotional material goes out, the marketing authorisation holder has two questions to answer. Has the person responsible for information checked it? Does the chosen channel need a step with the FAMHP? The responsible person’s check applies to all advertising. For the public, radio and television need a visa. Other channels need a notification at least thirty days before release.

Who reviews the advertising?

The rules are in the Royal Decree of 7 April 1995 on information and advertising for medicinal products for human use. The official consolidated text is available in French (opens in a new tab) and Dutch (opens in a new tab); there is no official English version.

  • Legal requirement. The marketing authorisation holder works with a person responsible for information approved by the Minister and notifies the FAMHP of that person’s name (Article 13 § 1). That person checks that information and advertising comply with the law (Article 13 § 4).
  • Qualifications. The person responsible for information is a pharmacist, a medical doctor, or holds a master’s degree in pharmaceutical sciences or medicine, with at least one year of experience in pharmaceutical information (Article 13 § 2).
  • FAMHP guidance. The FAMHP page on the person responsible for information (opens in a new tab) links to the designation form and to a Q&A in Dutch and French. According to that Q&A, the person responsible covers all medicines of one marketing authorisation holder. They may work for several companies if the contracts allow it.

In practice, the role is often called RIP or QP-RIP.

Which step does each channel need?

MaterialCheck by the person responsible for informationStep with the FAMHPLegal basis
Public advertising on radio or televisionYesVisa before broadcast; one visa per broadcast medium, with the visa number clearly visibleRoyal Decree of 7 April 1995, Art. 16 § 1 and Art. 17
Other public advertising (print, posters, online, point of sale)YesNotification at least thirty days before release, countersigned by the person responsible for informationRoyal Decree of 7 April 1995, Art. 16 § 2 and Art. 18
Reproduction of the approved package leafletYesNo visa and no notificationRoyal Decree of 7 April 1995, Art. 16 § 5
Advertising to people qualified to prescribe or dispenseYesNo visa or notification under Chapter VII; mandatory information appliesRoyal Decree of 7 April 1995, Art. 9

A few more rules complete the picture.

  • Only medicines designed for use without a doctor’s involvement in diagnosis, prescription or monitoring may be advertised to the public (Article 6).
  • The thirty-day notification period only starts once the FAMHP has received the fee (Article 16 § 2).
  • A visa or notification is valid for two years and can be renewed (Article 16 § 3).
  • If the marketing authorisation is withdrawn, or the medicine becomes prescription-only, the visa is withdrawn and the notification cancelled (Article 20).

The pre-publication workflow

This workflow combines legal requirements with our recommendations.

  1. Brief. Define the audience, channels and release date. Our advice.
  2. Product status. Check the dispensing status and work from the current SmPC. Legal requirement for public advertising: Article 6.
  3. Referenced draft. Link every claim to the SmPC or another verifiable source. Our advice.
  4. Check by the person responsible for information. Have the final version approved and keep a record of that approval. Legal requirement: Article 13 § 4. The written record is our advice.
  5. Channel step. Visa, notification or no step, as set out in the table. Legal requirement: Articles 16 to 18.
  6. Release. Publish only once the visa is granted or the notification period has passed. Legal requirement: Article 16.
  7. Follow-up. Track the two-year validity and withdraw old versions. Our advice, based on Article 16 § 3.

Two hypothetical cases

Case A, the public (hypothetical). A marketing authorisation holder plans a campaign for a non-prescription painkiller: a radio spot, online banners and a pharmacy poster. The radio spot needs a visa, and the visa number must appear in the spot. The banners and the poster need a notification at least thirty days before release. The person responsible for information countersigns both the visa application and the notification. Plan the campaign over several weeks, because Article 17 sets out successive review steps for the visa.

Case B, healthcare professionals (hypothetical). The same company prepares a detail aid for a prescription medicine aimed at general practitioners. This material needs no visa or notification with the FAMHP. The person responsible for information checks the content and the mandatory information under Article 9: name and composition, the SmPC sections on indications, posology, contraindications and adverse effects, the marketing authorisation holder and number, the dispensing status and the public price per pack. If the detail aid comes with an invitation to a symposium with hospitality, check the separate Mdeon visa obligation linked to Article 10 of the Law of 25 March 1964 on medicines.

Where approval often stalls

In our experience, three points often slow approval down:

  • a claim that goes beyond the SmPC;
  • an old version still in circulation, for example on social media;
  • a notification period counted without allowing for payment of the fee.

We act as person responsible for information and review promotional material: see our Information and Publicity service. Planning a campaign? Let’s discuss a review of your campaign.

ShareLinkedInWhatsAppEmail
Hendrik StaelsIndustrial pharmacist, founder of MEDCORHendrik Staels is an industrial pharmacist and the founder of MEDCOR. He holds named roles such as Responsible Person (GDP), Qualified Person (GMP) and PRRC for clients in Belgium and the Benelux.
About Hendrik

Reviewed by Hendrik Staels before publication. Information as at 15 November 2026. Rules and dates can change, so check the cited sources before you act. This guide is general information, not legal advice.

Training on the advertising rules?

MEDCOR Academy opens soon with a short online course on the RIP role in Belgium. Join the waitlist and we will let you know when it opens.

Join the waitlist